HealthTree Logo
search more_vert
close
person Sign In / Create Account
Expanding Treatment Horizons with Immunotherapy
Posted: Apr 15, 2024
Expanding Treatment Horizons with Immunotherapy image

In recent years, significant breakthroughs have occurred in blood cancer treatment, creating new possibilities and raising hopes for improved outcomes. One major stride is the development of immunotherapy, a treatment approach using the patient's own immune system to destroy cancer cells. Dr. Yilmaz, a lymphoma expert from UT Southwestern in Dallas, Texas, joins HealthTree to discuss immunotherapy and how it is already being used to treat patients with advanced disease.

Immunotherapy offers a promising avenue for patients who have exhausted conventional therapies. Among the various modalities within immunotherapy are chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies. While initially approved for patients with refractory (not responding to treatment) cancer, these therapies are now being explored as frontline (initial) treatments to hopefully further improve cure rates for newly diagnosed patients.

At UT Southwestern, researchers are actively engaged in clinical trials evaluating different immunotherapies in refractory (not responding to treatment) cases and untreated patients. Moreover, targeted therapies tailored to specific molecules within tumor cells are also being studied alongside immunotherapy. This personalized approach to treatment aims to improve patient response while minimizing side effects.

Another avenue that researchers are exploring is combining and sequencing CAR T-cell therapies with bispecific antibodies, which could maximize their potential. The journey towards improved cancer treatment is multifaceted and ongoing. However, continued innovation and collaboration will achieve higher cure rates and better patient outcomes.

To learn more about DLBCL from other lymphoma specialists, watch our modules from HealthTree University.  

The author Kat Richardson

about the author
Kat Richardson

Kat is from Lehi, Utah and is the Health Education Manager for lymphoma. She has worked in healthcare for a decade now, and earned her degree in Community Health Education and Promotion. Kat is passionate about disease prevention as well as improving quality of life and health equity. She enjoys reading, hiking, baking, ice skating, gardening, time with her family and friends, and most of all, spoiling her nieces and nephew. 

Get the latest thought leadership on Diffuse Large B Cell Lymphoma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Diffuse Large B Cell Lymphoma Newsletter" for Diffuse Large B Cell Lymphoma news, life with Diffuse Large B Cell Lymphoma stories, Diffuse Large B Cell Lymphoma clinical trials, Diffuse Large B Cell Lymphoma 101 articles and events with Diffuse Large B Cell Lymphoma experts.

Thanks to our HealthTree Community for Diffuse Large B Cell Lymphoma Sponsors:

Regeneron
Bristol Myers Squibb

Follow Us

facebook instagram youtube